Literature DB >> 11992529

Strategies for manipulating the relative concentration of recombinant rotavirus structural proteins during simultaneous production by insect cells.

Laura A Palomares1, Susana López, Octavio T Ramírez.   

Abstract

Adequate production strategies of virus-like particles are among the challenges that must be addressed before such complex multimeric structures find practical applications as vaccines. Attainment of the correct stoichiometric relation between proteins that constitute virus-like particles should result in an increased productivity by maximizing the concentration of assembled proteins and preventing the accumulation of waste monomers. In this work, strategies for manipulating the relative concentration between two of the structural proteins that constitute rotavirus-like particles (VP2 and VP6) were explored using the insect cell baculovirus expression vector system. It was shown that multiplicity of infection is a useful tool for manipulating protein production rates and maximum concentrations in cultures expressing one or two recombinant proteins. Thus, multiplicity of infection can be employed for improving production of rotavirus-like particles. VP2 and VP6 production rates obtained during individual infections remained unchanged when both were simultaneously produced, indicating that such rates can be utilized for estimating protein concentrations during coexpression. Manipulation of the time of infection between the two recombinant baculoviruses, proposed here for the first time, also proved to be effective for controlling the relative protein concentrations. The use of such sequential infections constituted an effective production alternative that does not require high amounts of virus stocks and is easy to implement. In addition to VP2 and VP6, kinetic parameters for the individual production of the other two proteins (VP4 and VP7) that constitute rotavirus-like particles were also obtained. Copyright 2002 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11992529     DOI: 10.1002/bit.10243

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  6 in total

1.  Self-assembly of the recombinant capsid protein of a bovine norovirus (BoNV) into virus-like particles and evaluation of cross-reactivity of BoNV with human noroviruses.

Authors:  M G Han; Q Wang; J R Smiley; K O Chang; L J Saif
Journal:  J Clin Microbiol       Date:  2005-02       Impact factor: 5.948

2.  Incorporation of GM-CSF or CD40L Enhances the Immunogenicity of Hantaan Virus-Like Particles.

Authors:  Lin-Feng Cheng; Fang Wang; Liang Zhang; Lan Yu; Wei Ye; Zi-Yu Liu; Qi-Kang Ying; Xing-An Wu; Zhi-Kai Xu; Fang-Lin Zhang
Journal:  Front Cell Infect Microbiol       Date:  2016-12-20       Impact factor: 5.293

3.  N-Glycan Modification of a Recombinant Protein via Coexpression of Human Glycosyltransferases in Silkworm Pupae.

Authors:  Tatsuya Kato; Natsumi Kako; Kotaro Kikuta; Takatsugu Miyazaki; Sachiko Kondo; Hirokazu Yagi; Koichi Kato; Enoch Y Park
Journal:  Sci Rep       Date:  2017-05-03       Impact factor: 4.379

Review 4.  Co-expression vs. co-infection using baculovirus expression vectors in insect cell culture: Benefits and drawbacks.

Authors:  Stanislav Sokolenko; Steve George; Andreas Wagner; Anup Tuladhar; Jonas M S Andrich; Marc G Aucoin
Journal:  Biotechnol Adv       Date:  2012-01-28       Impact factor: 14.227

5.  Recombinant outer capsid glycoprotein (VP7) of rotavirus expressed in insect cells induces neutralizing antibodies in rabbits.

Authors:  M Khodabandehloo; M Shamsi Shahrabadi; H Keyvani; B Bambai; Za Sadigh
Journal:  Iran J Public Health       Date:  2012-05-31       Impact factor: 1.429

6.  Population kinetics during simultaneous infection of insect cells with two different recombinant baculoviruses for the production of rotavirus-like particles.

Authors:  Jimmy A Mena; Octavio T Ramírez; Laura A Palomares
Journal:  BMC Biotechnol       Date:  2007-07-04       Impact factor: 2.563

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.